ZYNERBA PHARMACEUTICALS INC (ZYNE) Stock Analyst Earnings Estimates
NASDAQ:ZYNE - Nasdaq - US98986X1090 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 10K -96.43% | -100.00% | 90K | -100.00% | 11.475M | 48.855M 325.75% | 189.7M 288.29% | 372.12M 96.16% | 594.44M 59.74% | 877.79M 47.67% | 647.6M -26.22% | |||||
| EBITDA YoY % growth | -23.13M -85.04% | -32.73M -41.50% | -40.3M -23.13% | N/A 15.16% | -50.184M -51.65% | -39.372M 29.56% | -36.414M 4.08% | -44.778M -27.82% | -52.02M -16.17% | -34.578M 33.53% | -5.712M 83.48% | 70.584M 1,335.71% | 164.22M 132.66% | 268.77M 63.66% | 379.95M 41.37% | |
| EBIT YoY % growth | -23.21M -85.24% | -32.82M -41.40% | -40.4M -23.10% | -35.828M 15.05% | -52.911M -51.69% | -39.487M 29.37% | -36.763M 4.13% | -44.068M -25.01% | -53.531M -21.47% | -12.27M 77.08% | 92.274M 852.06% | 255.18M 176.55% | 923.4M 261.86% | 714.54M -22.62% | 377.91M -47.11% | |
| Operating Margin | -232,100.00% | N/A | -44,888.89% | N/A | N/A | N/A | N/A | N/A | -466.50% | -25.11% | 48.64% | 68.57% | 155.34% | 81.40% | 58.36% | |
| EPS YoY % growth | -2.56 -5.12% | -2.47 3.52% | -2.71 -9.72% | -1.57 31.00% | -1.95 -4.28% | -0.99 52.31% | -0.84 10.75% | -0.85 -2.82% | -0.64 25.00% | -0.37 41.57% | 0.53 240.45% | 1.60 204.85% | 2.88 79.94% | 3.28 13.98% | 4.20 27.95% |
All data in USD
| Q3 / 23 | Q4 / 23 | Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.09 145.90% | -0.22 -21.83% | -0.09 58.71% | 0.08 136.43% | -0.22 -344.44% | -0.26 -18.60% |
| Revenue Q2Q % growth | 15.3M | 7.65M | 15.3M | -100.00% | ||
| EBITDA Q2Q % growth | -11.424M -37.19% | -11.934M -40.95% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | 3.834M 145.14% | -11.862M -36.57% | -5.284M 49.54% | 1.643M 114.75% | -13.671M -456.56% | -16.185M -36.44% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2023 Q2Q % growth | -0.21 12.50% | -0.20 | -0.01 | -4.68% |
| Q1 2023 Q2Q % growth | -0.21 | -0.19 | -0.02 | -8.36% |
| Q4 2022 Q2Q % growth | -0.18 18.18% | -0.19 | 0.01 | 4.61% |
| Q3 2022 Q2Q % growth | -0.20 23.08% | -0.23 | 0.03 | 12.85% |
| Q2 2022 Q2Q % growth | -0.24 4.00% | -0.23 | -0.01 | -2.75% |
| Q1 2022 Q2Q % growth | -0.21 -5.00% | -0.23 | 0.02 | 10.02% |
| Q4 2021 Q2Q % growth | -0.22 33.33% | -0.27 | 0.05 | 18.09% |
| Q3 2021 Q2Q % growth | -0.26 16.13% | -0.26 | 0.00 | -1.15% |
| Q2 2021 Q2Q % growth | -0.25 67.95% | -0.24 | -0.01 | -2.98% |
| Q1 2021 Q2Q % growth | -0.20 62.26% | -0.25 | 0.05 | 21.39% |
| Q4 2020 Q2Q % growth | -0.33 28.26% | -0.34 | 0.01 | 1.53% |
| Q3 2020 Q2Q % growth | -0.31 29.55% | -0.44 | 0.13 | 29.74% |
| Q2 2020 Q2Q % growth | -0.78 -56.00% | -0.46 | -0.32 | -70.96% |
| Q1 2020 Q2Q % growth | -0.53 -12.77% | -0.51 | -0.02 | -4.52% |
| Q4 2019 Q2Q % growth | -0.46 | -0.51 | 0.05 | 10.32% |
| Q3 2019 Q2Q % growth | -0.44 | -0.53 | 0.09 | 17.25% |
| Q2 2019 Q2Q % growth | -0.50 | -0.51 | 0.01 | 1.30% |
| Q1 2019 Q2Q % growth | -0.47 | -0.50 | 0.03 | 5.64% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 145% | 0% | -4.91% |
| Revenue | 99900% | N/A | N/A | N/A |